BioXcel Therapeutics (BTAI) Raw Materials (2022 - 2026)

BioXcel Therapeutics' Raw Materials history runs 5 years deep, the most recent figure standing at $408000.0 for Q1 2026.

• In Q1 2026, Raw Materials fell 12.07% year-over-year to $408000.0; the TTM figure through Mar 2026 stood at $408000.0 (down 12.07% YoY), while the FY2025 annual figure was $317000.0, down 37.35% from the prior year.
• Raw Materials was $408000.0 for Q1 2026 at BioXcel Therapeutics, up from $317000.0 in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $935000.0 in Q4 2023 to a low of $317000.0 in Q4 2025.
• Historically, Raw Materials has averaged $635625.0 across 5 years, with a median of $682000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Raw Materials soared 37.1% in 2023, then sank 52.7% in 2025.
• A 5-year view of Raw Materials shows it stood at $682000.0 in 2022, then jumped by 37.1% to $935000.0 in 2023, then tumbled by 45.88% to $506000.0 in 2024, then tumbled by 37.35% to $317000.0 in 2025, then grew by 28.71% to $408000.0 in 2026.
• The last three Raw Materials figures came in at $408000.0 (Q1 2026), $317000.0 (Q4 2025), and $394000.0 (Q3 2025), per Business Quant data.